Please assess the completion status of the following clinical trial:

Trial Title: Phase IIB Rheumatoid Arthritis Dose Ranging Study for BMS-945429 in Subjects Who Are Not Responding to Methotrexate

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 7.0

Eligibility Criteria:
Inclusion Criteria:~* Inadequate response to Methotrexate~* Must have been taking Methotrexate for at least 3 months at a minimal weekly dose of at least 15 mg and stable dose for 4 weeks prior to randomization~* American College of Rheumatology (ACR) global function status class 1-3~* Minimum of 6 swollen and 6 tender joints with evidence of synovitis in at least 1 hand or wrist~* High sensitivity C-reactive protein (hsCRP) ≥ 0.8 mg/dL~Exclusion Criteria:~* Previously received or currently receiving concomitant biologic therapy

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Arm 1 (Type: PLACEBO_COMPARATOR): BMS-945429 Placebo/BMS-945429+Methotrexate+Adalimumab Placebo
- Arm 2 (Type: EXPERIMENTAL): BMS-945429 + Methotrexate + Adalimumab Placebo
- Arm 3 (Type: EXPERIMENTAL): BMS-945429 + Methotrexate + Adalimumab Placebo
- Arm 4 (Type: EXPERIMENTAL): BMS-945429 + Methotrexate + Adalimumab Placebo
- Arm 5 (Type: EXPERIMENTAL): BMS-945429 + Methotrexate/Methotrexate Placebo + Adalimumab Placebo
- Arm 6 (Type: EXPERIMENTAL): BMS-945429 + Methotrexate/Methotrexate Placebo+Adalimumab Placebo
- Arm 7 (Type: ACTIVE_COMPARATOR): Adalimumab + Methotrexate

Based on this trial design, predict the completion outcome and termination type (if applicable).